Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers.

bioRxiv : the preprint server for biology·2026
Same author

FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.

Cancer research·2026
Same author

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Cell tumbling enhances stem cell differentiation in hydrogels via nuclear mechanotransduction.

Nature materials·2024
Same author

Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.

Cancer discovery·2024

Related Experiment Video

Updated: Jan 16, 2026

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
07:43

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics

Published on: May 3, 2024

4.3K

Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities.

Eunice Lopez-Fuentes1, Andrew S Clugston1, Alex G Lee1

  • 1Division of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California.

Cancer Discovery
|October 2, 2025
PubMed
Summary

Epigenetic mechanisms drive distinct osteosarcoma subtypes, identified as early osteoblast-derived (EOD) and late osteoblast-derived (LOD) states. These subtypes exhibit differential drug responses, paving the way for targeted osteosarcoma therapies.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Related Experiment Videos

Last Updated: Jan 16, 2026

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
07:43

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics

Published on: May 3, 2024

4.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Area of Science:

  • Oncology
  • Epigenetics
  • Genomics

Background:

  • Osteosarcoma is a complex cancer with limited targeted therapies due to genomic heterogeneity.
  • Epigenetic dysregulation is increasingly recognized as a driver of cancer complexity and heterogeneity.

Purpose of the Study:

  • To investigate the role of epigenetic mechanisms in driving distinct osteosarcoma subtypes.
  • To identify and characterize cellular states within osteosarcoma based on epigenetic profiles.
  • To explore the therapeutic implications of these identified subtypes.

Main Methods:

  • Chromatin accessibility profiling to identify distinct cell states.
  • Multiomic single-cell analysis to define core regulatory circuitries.
  • Utilizing patient-derived xenograft models to assess differential drug responses.

Main Results:

  • Identification of two osteosarcoma cell states: early osteoblast-derived (EOD) and late osteoblast-derived (LOD).
  • EOD and LOD states are characterized by distinct transcription factor profiles related to bone development.
  • These cell states co-exist within tumors and exhibit differential responses to therapies in preclinical models.

Conclusions:

  • Epigenetic heterogeneity defines distinct osteosarcoma subtypes with therapeutic relevance.
  • Understanding these epigenetic subtypes is crucial for developing effective combination therapies for osteosarcoma.
  • This work highlights the potential of epigenetic subtyping in complex cancers.